Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.285
-0.530-5.40%
Volume:92.21M
Turnover:878.44M
Market Cap:106.98B
PE:23.34
High:10.040
Open:9.880
Low:9.235
Close:9.815
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.56
T/O Rate:0.80%
Dividend:0.34
Dividend Rate:3.64%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.43
PE(LYR):23.34
PS:2.92

Loading ...

CSPC Pharmaceutical Group Stock Climbs 1.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 22

Innovative Drug Stocks Rally as Index Surges Over 6% on Multiple Positive Catalysts, Led by Key Players

Deep News
·
Sep 21

CSPC PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 4.85%

HK Disclosure
·
Sep 21

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

CSPC Pharmaceutical Group Stock Climbs 7.6% in Hong Kong

Dow Jones
·
Sep 21

Hang Seng Index Rallies into the Close, up More Than 1%, Testing the 25,000 Level

Tiger Newspress
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

Hong Kong Stocks Open Flat as Pharma Shares Lead Gains; Innovent Rises Nearly 2%

Stock News
·
Sep 21

Movement Alert|CSPC PHARMA Rises 3.02% in Regular Trading, Boosted by Strong H1 Earnings and Pipeline Milestones

Market Focus
·
Sep 21

CSPC Pharmaceutical Group Stock Rises 0.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 18

Movement Alert|CSPC PHARMA Rises 3.45% in Regular Trading, H1 Adjusted Net Profit Surges 165.8% on Strong Innovative Drug Revenue

Market Focus
·
Sep 18

CSPC Pharmaceutical Invites New Shareholders to Opt for Electronic Corporate Communications; Default Choice Effective 17 Oct 2026

Bulletin Express
·
Sep 17

CSPC Pharma H1 2026: Profit Surges 139%, License Fees Drive 57% Finished-Drug Growth

Bulletin Express
·
Sep 17

CSPC Pharmaceutical Publishes 2026 Interim Report Online; Shareholders May Request Printed Copies

Bulletin Express
·
Sep 17

CSPC Pharma Begins Diabetes Drug Trial in China

MT Newswires Live
·
Sep 16

CSPC Pharma Initiates Phase II Clinical Trial of SYH2069 Injection for Type 2 Diabetes at First Chinese Study Center

Stock News
·
Sep 16

CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug

MT Newswires Live
·
Sep 15

Cspc Pharmaceutical Says Sys6010 Granted Breakthrough Therapy Designation by NMPA

Reuters
·
Sep 15

CSPC Pharma's Novel Drug SYS 6010 Receives Breakthrough Therapy Designation in China for Advanced Non-Small Cell Lung Cancer

Stock News
·
Sep 15

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for Nsclc

THOMSON REUTERS
·
Sep 15